Cochrane · systematic review · CD007791
Pharmacological treatments for Friedreich ataxia
Kearney, M, Orrell, RW, Fahey, M, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
NeuromuscularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
5
No studies
1
Included studies
NR
No studies 1 · 16.7%Ungraded 0 · 0%Very low 2 · 33.3%Low 3 · 50%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Antioxidant versus placebo for Friedreich ataxia
Population: people with Friedreich ataxia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Ataxia rating score ICARS; range 0 to 100) Antioxidant vs placebo | no estimate extracted | 2 studies · 72 participants | Low Downgraded: risk of bias, imprecision, inconsistency, publication bias |
Ejection fraction Antioxidant vs placebo | no estimate extracted | 1 study · 28 participants | Very low Downgraded: imprecision, indirectness |
End‐diastolic interventricular septal thickness (IVSTd) Measured in mm Antioxidant vs placebo | no estimate extracted | 2 studies · 72 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Left ventricular mass (LVM) Measured in g Antioxidant vs placebo | no estimate extracted | 1 study · 28 participants | Low Downgraded: imprecision, indirectness, publication bias |
Survival (not measured) Antioxidant vs placebo | no estimate extracted | NR | No studies |
Severe adverse events Antioxidant vs placebo | RR 1 [0.07, 15] | 2 studies · 72 participants | Low Downgraded: imprecision |